Back to today’s briefing

Story perspectives

CDC Endorses Lenacapavir: Advocates Demand Insurance Coverage

9/23/2025

33 6

Summary

Story summary

On September 18, the CDC recommended Lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP) to boost insurance coverage.
Lenacapavir, FDA-approved in June, is the first twice-yearly injectable PrEP with high efficacy in trials.
Yet only about one-third of eligible people use PrEP, and insurers hesitate over a $28,218 annual price; advocates press CVS Health to cover Lenacapavir.

1 of 1

Story summary

On September 18, the CDC recommended Lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP) to boost insurance coverage.
Lenacapavir, FDA-approved in June, is the first twice-yearly injectable PrEP with high efficacy in trials.
Yet only about one-third of eligible people use PrEP, and insurers hesitate over a $28,218 annual price; advocates press CVS Health to cover Lenacapavir.